Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2005-03-15
2005-03-15
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C530S387900, C530S388250, C530S389300
Reexamination Certificate
active
06866845
ABSTRACT:
The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a antibodies for the prevention and treatment of sepsis in humans as well as other animals. The present invention also relates to methods of generating anti-C5a antibodies employing C-terminal truncated C5a peptides.
REFERENCES:
patent: 4357272 (1982-11-01), Polson
patent: 4686100 (1987-08-01), Raffin et al.
patent: 5051448 (1991-09-01), Shashoua
patent: 5169862 (1992-12-01), Burke, Jr. et al.
patent: 5192746 (1993-03-01), Lobl et al.
patent: 5260203 (1993-11-01), Ladner et al.
patent: 5340923 (1994-08-01), Carroll
patent: 5539085 (1996-07-01), Bischoff et al.
patent: 5559103 (1996-09-01), Gaeta et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5576423 (1996-11-01), Aversa et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5904922 (1999-05-01), Carroll
patent: 0025949 (1981-04-01), None
patent: 0245993 (1987-11-01), None
patent: WO 9639503 (1996-12-01), None
Abaza et al. J. of Protein Chemistry, 11(5):433-444, 1992.*
Czermak et al. Nature Medicine, 5(7):788-792) (1999).*
Ames Rs et al., “Isolation of Neutralizing Anti-C5a Monoclonal Antibodies from a Filamentous Phage Monovalent Fab Display Library,”J. Immunol152:4572-4581 (1994).
R.C. Bone, “The Pathogenesis of Sepsis,”Ann. Intern. Med. 115:457-469 (1991).
E.S. Caplan and N. Hoyt, “Infection Surveillance and Control in the Severely Traumatized Patient,”Am. J. Med. 70:638-640 (1981).
Caruthers et al., “New chemical methods for synthesizing polynucleotides,”Nuc. Acids Res. Symp. Ser. 7:215-233 (1980).
Chow and Kempe, “Synthesis of oligodeoxyribonucleotides on silica gel support,”Nuc. Acids Res. 9:2807-2817 (1981).
Crea and Horn, “Synthesis of oligonucleotides on cellulose bya phosphotriester method,”Nuc. Acids. Res. 9:2331 (1980).
Czermak BJ. et al., “Protective effects of a C5a blockade in sepsis,”Nature Medicine5:788-792 (1999).
Elzaim, et al., “Generation of Neutralizing Antipeptide Antibodies to the Enzymatic Domain ofPseudomonas aeruginosaExotoxin A.”Infect. Immun. May;66(5):2170-9 (1998).
Evans et al., “An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies,”Nature339:385-388 (1989).
Gerard C. et al., “Amino Acid Sequence of the Anaphylatoxin from the fifth Component of Porcine Complement,”J. Biol. Chem. 255(10), 4710-4715, (1980).
Gluzman, “SV40-Transformed Simian Cells Support the Replication of early SV40 Mutants,”Cell, 23:175-182 (1981).
Hatherhill JR et al., “Effects of Anti-C5a Antibodies on Human Polymorphonuclear Leukocyte Function: Chemotaxis. Chemiluminescence, and Lysosomal Enzyme Release”J of Biological Response Modifiers8:614-624 (1989).
Hill, J.H. and Ward, P.A., “The Philogistic Role of C3 Leukotactic Fragments in Myocardial Infarts of Rats,”J. Exp. Med. 133:885-900 (1971).
Hochuli et al., “New Metal Chelate Adsorbent Selective for Proteins and Peptides Containing Neighbouring Histidine Residues,”J Chromatography411:177-184 (1987).
A.M. Hoffman et al.,“Prognostic Variables for Survival of Neonatal Foals Under Intensive Care,”J. Vet. Int. Med. 6:89-95 (1992).
Huang et al.,“Vaccinia Virus Recombinants Expressing an 11-Kilodalton β-Galactosidase Fusion Protein Incorporate Active β-Galactosidase in Virus Particles,”J. Virol. 62:3855-3861 (1988).
W.K. Joklik et al., (eds.),Zinsser Microbiology, 18th ed., Chapter 27Streptococcus pneumoniae, p. 485-489, Appleton-Century-Crofts, Norwalk, CT (1984).
Kettleborough, et al.,“Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation,”Protein Engineering4(7):773-783 (1991).
Kohl, J.,and Bitter-Suermann, D.,Anaphylatoxins. Complement in health and disease., Edited by Whaley, K., Loos. M., Weiler, J.M., Kluwer Academic publishers, pp 299-324 (1993).
Kohler, G. and Milstein, C., “Continuous cultures of fused cells secrecting antibody of predined specificity,”Nature256:495-497 (1975), Jun. 23, 2003.
Kola et al., “Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display synthetic peptides and site-directed mutagenesis”.Immunotechnology1:115-126 (1996).
Kozbor and Roder, “The production of monoclonal antibodies from human lymphocytes,”Immunol. Today4:72-79 (1983).
Larrick JW et al., “Characterization of Murine Monoclonal Antibodies That Recognize Neutralizing Epitopes on Human C5a”Infection and Immunity55:1867-1872 (1987).
G.W. Machiedo et al.,“Patterns of Mortality in a Surgical Intensive Care Unit,”Surg. Gyn&Obstet. 152:757-759 (1981).
Mandecki W, et al.,“Chemical synthesis of a gene encoding the human complement fragment C5a and its expression inEscherichia coli,” Proc Natl Acad Sci U S A. 82(11):3543-7 (1985).
Matteucci and Caruthers,“The Synthesis of Oligodeoxypyrimidines on a Polymer Support,”Tetrahedron Lett21:719-722 (1980).
M. Meek et al.,“The Baltimore Sepsis Scale: Measurement of Sepsis in Patients with Burns Using a New Scoring System,”J. Burn Care Rehab. 12:564-568 (1991).
Mohr M. et al., “Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis,”Eur J Clin Invest28:227-234 (1998).
D.D. Morris et al.,“Endotoxemia in neonatal calves given antiserum to a mutantEscherichia coli(J-5),”Am. J. Vet. Res. 47:2554-2565 (1986).
Mulligan, M.S. et al.,“Requirement and Role of C5a in Acute Lung Inflammatory Injury in Rats,”J. Clin. Invest. 98:503-512 (1996).
Nardelli et al.,“A Chemically Defined Synthetic Vaccine Model for HIV-1,”J. Immunol. 148:914-920 (1992).
R.L. Nichols inDecision Making in Surgical Sepsis, B.C. Decker, Inc., Philadelphia, “Classification of Surgical Wounds and Nonoperative Factors Influencing Surgical Wound Infections,” pp. 20-21 (1991).
Nilsson et al., “Affinity Fusion Strategies for Detection, Purification, and Immobilization of Recombinant Proteins,”Protein Expression and Purification11:1-16 (1997).
Olson, L.M., et al.,“The Role of C5 in Septic Lung Injury,”Ann. Surg. 202:771-776 (1985).
Park K.W. et al., “Attenuation of Endothelium-Dependent Dilation of Pig Pulmonary Arterioles After Cardiopulmonary Bypass Is Prevented by Monoclonal Antibody to Complement C5a,”Anesth Analg89:42-48 (1999).
Posnett et al.,“A Novel Method for Producing Anti-peptide Antibodies,”JBC263:1719-1725 (1988).
Protein Accession No. A57689/ GI “2118416”.
Protein Accession No. P01032/ GI “116605”.
Protein Accession No. P12082/ GI “116604”.
Roberge et al.,“A Strategy for a Convergent Synthesis of N-Linked Glycopeptides on a Solid Support,”Science269:202-204 (1995).
Rothermel et al., Nucleotide and corrected amino acid sequence of the functional recombinant rat anaphylatoxin C5a,Biochim. Biophys. Acta1351:9-12, (1997).
Schlienger et al.,“Human Immunodeficieny Virus Type 1 Major Neutralizing Determinant Exposed on Hepatitis B Surface Antigen Particles is Highly Immunogenic in Primates,”J. Virol. 66:2570-2576 (1992).
K.A. Schulman et al.,“Cost-effectiveness of HA-1A Monoclonal Antibody for Gram-Negative Sepsis,”JAMA266:3466-3471 (1991).
J.M. Slack and I.S. Snyder,Bacteria and Human Disease, pp. 128-133, Yearbook Medical Publishers (1978).
Solomkin, et al.,“Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation,”Surgery90:319-327, (1981).
Stahel, et al.,“TNF-α-Mediated Expression of the Receptor for Anaphylatoxin C5a on Neurons in Experimental Listeria Men
Huber-Lang Markus
Sarma Vidya
Ward Peter A.
Chan Christina
Medlen & Carroll LLP
The Regents of the University of Michigan
Vander Vegt F. Pierre
LandOfFree
Compositions and methods for the treatment of sepsis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment of sepsis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of sepsis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3416021